Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa Barbara Spitzer, Miguel-Angel Perales, Nancy A. Kernan, Susan E. Prockop, Emily C. Zabor, Nicholas Webb, Hugo Castro-Malaspina, Esperanza B. Papadopoulos, James W. Young, Andromachi Scaradavou, Rachel Kobos, Sergio A. Giralt, Richard J. O'Reilly, Farid Boulad Biology of Blood and Marrow Transplantation Volume 22, Issue 8, Pages 1449-1454 (August 2016) DOI: 10.1016/j.bbmt.2016.05.001 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Overall and disease-free survival curves (A) and cumulative incidence of relapse (B) across all patients. Biology of Blood and Marrow Transplantation 2016 22, 1449-1454DOI: (10.1016/j.bbmt.2016.05.001) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Overall survival (A) and cumulative incidence of relapse (B) stratified by remission duration of ≤6 months or >6 months, demonstrating significantly improved survival and lower incidence of relapse for patients with remission durations greater than 6 months after their initial allo-HSCT (P < .001). Biology of Blood and Marrow Transplantation 2016 22, 1449-1454DOI: (10.1016/j.bbmt.2016.05.001) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions